Our Portfolio

Egle Therapeutics

Approach: Engineered and targeted cytokines to treat autoimmune diseases

Strategic Area: Immunotherapies

T1D Funding Impact: Bringing T1D focus and experience to a multi-indication drug

Abata Therapeutics

Approach: Advancing a novel treatment modality for T1D enabling next-generation immune therapies

Strategic Area: Immunotherapies

T1D Funding Impact: Supporting discovery and development work for T1D alongside strong life sciences investor syndicate

Bigfoot Biomedical

Approach: Developing a comprehensive diabetes management ecosystem to reduce the burden of diabetes for insulin-dependent individuals living with T1D and T2D

Strategic Area: Improving Lives

T1D Funding Impact: Accelerating the development of interoperable automated insulin delivery systems for people with T1D

AnTolRx, Inc.

Approach: Developing antigen-specific immune tolerance therapies for autoimmune and allergic diseases

Strategic Area: Immunotherapies

T1D Funding Impact: Catalyzing company formation and T1D program, together with a pharmaceutical company partner

Biolinq

Approach: Developing a wirelessly-enabled biosensor patch capable of continuously monitoring multiple biomarkers. Initially focused on a minimally-invasive continuous glucose monitor (CGM) for people with diabetes

Strategic Area: Improving Lives

T1D Funding Impact: Accelerating the development of a clinical-stage next gen sensing platform

Capillary Biomedical

Approach: Clinical-stage novel extended wear insulin infusion set technology to improve the lives of people with T1D on insulin pump therapy

Strategic Area: Improving Lives

T1D Funding Impact: Supporting the development and entry to the clinic of a novel long wear infusion set system for clinical benefit and comfort

Code Biotherapeutics

Approach: Developing a targeted regenerative agent to restore functional beta cell mass

Strategic Area: Beta Cell Therapies

T1D Funding Impact: Bringing T1D focus and experience to a multi-indication platform company

Diasome Pharmaceuticals

Approach: Developing a clinical stage liver-targeted insulin for improved glycemic control

Strategic Area: Improving Lives

T1D Funding Impact: Catalyzing financing alongside VC lead to complete critical clinical studies

DiogenX

Approach: Developing a regenerative agent to restore functional beta cell mass

Strategic Area: Beta Cell Therapies

T1D Funding Impact: Supporting a T1D-focused company founded on compelling science with transformational potential

eGenesis Bio

Approach: Creating a renewable islet source from animal organs

Strategic Area: Beta Cell Therapies

T1D Funding Impact: Bringing T1D experience to a platform company

GluSense Medical

Approach: Developing a long-term implantable continuous glucose monitor (CGM) for diabetes patients

Strategic Area: Improving Lives

T1D Funding Impact: Funding to critical value inflection points

Enthera

Approach: Developing antibodies that inhibit beta cell death

Strategic Area: Beta Cell Therapies

T1D Funding Impact: Bringing T1D focus and experience to a multi-indication drug

GentiBio

Approach: Advancing a novel treatment modality for T1D enabling next-generation immune therapies

Strategic Area: Immunotherapies

T1D Funding Impact: Supporting T1D-focused company to advance a promising immunotherapy work alongside strong life sciences investor syndicate

i2o Therapeutics

Approach: Developing a platform of ionic liquids to enable oral drug delivery of insulin and other therapies

Strategic Area: Improving Lives

T1D Funding Impact: Accelerate the development of a delivery platform enabling oral insulin dosing for more physiologic glucose control

ImmusanT

Approach: Developing a peptide desensitization therapy for T1D

Strategic Area: Immunotherapies

T1D Funding Impact: Catalyzing the creation of a T1D-focused program using a powerful platform

Immunocore

Approach: Soluble TCR bi-specific approach for safer, durable, tissue-specific immunomodulation to preserve beta cells

Strategic Area: Immunotherapies

T1D Funding Impact: Catalyzing the acceleration of a T1D-focused autoimmune program using a powerful platform

IM Therapeutics

Approach: Precision medicine platform developing small molecules blockers of autoimmunity

Strategic Area: Immunotherapies

T1D Funding Impact: Advancing second generation of genetically targeted blockers

Kriya Therapeutics

Approach: Using gene therapy to achieve insulin independence in established T1D

Strategic Area: Beta Cell Therapies

T1D Funding Impact: Bringing T1D expertise to a next-generation gene therapy platform company focused on prevalent and severe chronic diseases

Inversago Pharma

Approach: Developing an oral drug to promote beta cell functional recovery

Strategic Area: Beta Cell Therapies

T1D Funding Impact: Bringing T1D focus and experience to a multi-indication drug

Pandion Therapeutics

Approach: Islet-targeted immunotherapies for safer, durable treatments

Strategic Area: Immunotherapies

T1D Funding Impact: Catalyzing the creation of a T1D-focused program using a powerful platform (TO BE ACQUIRED BY MERCK IN 2021)

Protomer Technologies

Approach: Developing a highly-sensitive glucose-responsive insulin

Strategic Area: Improving Lives

T1D Funding Impact: Accelerating the development of a novel insulin formulation

Provention Bio

Approach: Building and advancing a diversified portfolio of advanced clinical-stage and pre commercial-stage candidates that intercept, prevent or delay the progression of debilitating, life-impacting, and life-threatening diseases such as type 1 diabetes, celiac disease, and lupus (NASDAQ: PRVB)

Strategic Area: Immunotherapies

T1D Funding Impact: Facilitated the acquisition and clinical development of T1D-relevant assets (IPO JULY 2018)

Repertoire Immune Medicines

Approach: Decoding the targets of disease-causing T cells to develop immunotherapy treatments

Strategic Area: Immunotherapies

T1D Funding Impact: Catalyzing the creation of a T1D program using a powerful discovery platform

Sana Biotechnology

Approach: Developing a cell replacement therapy using hypoimmune iPSC-derived islets to achieve insulin independence

Strategic Area: Beta Cell Therapies

T1D Funding Impact: Accelerating the iPSC program to provide a renewable cell source that does not require immunosuppression

Semma Therapeutics

Approach: Combining proprietary cells with state-of-the-art devices towards insulin independence

Strategic Area: Beta Cell Therapies

T1D Funding Impact: Funding development of beta cell replacement therapy with JDRF collaboration (ACQUIRED BY VERTEX SEPT. 2019)

Seraxis

Approach: Developing a cell replacement therapy for insulin-dependent diabetes towards a functional cure

Strategic Area: Beta Cell Therapies

T1D Funding Impact: Supporting a T1D-focused company to advance a promising beta cell replacement therapy alongside strategic and financial investors

SQZ Biotech

Approach: Creating an off-the shelf cell therapy to retrain the immune system

Strategic Area: Immunotherapies

T1D Funding Impact: Catalyzing the creation of a T1D-focused program and a new tolerance effort on a compelling platform

Sonoma Biotherapeutics

Approach: Developing a promising immune modulator to preserve beta cell function

Strategic Area: Immunotherapies

T1D Funding Impact: Accelerating the development of targeted therapy for T1D

TetraGenetics

Approach: Engineering a first-in-class, disease modifying immune therapy to prevent beta cell destruction

Strategic Area: Immunotherapies

T1D Funding Impact: Aiding in securing a downstream strategic partner for asset development

Veralox Therapeutics

Approach: Developing a therapeutic to inhibit beta cell stress

Strategic Area: Beta Cell Therapies

T1D Funding Impact: Accelerating the development of early stage therapy for T1D, catalyzing matching participation from other investors

vTv Therapeutics

Approach: Activating liver glucokinase to decrease frequency of hypoglycemic events and lower HbA1c

Strategic Area: Improving Lives

T1D Funding Impact: Funding late stage clinical studies to build a data package for regulatory approval

Sab Biotherapeutics

Approach: Platform to development fully-human antibody therapies with improved safety and pharmacological properties for treating autoimmune and infectious diseases.

Strategic Area: Immunotherapies

T1D Funding Impact: Advancing a next generation of an effective immune modulating therapy for T1D.

COUR Pharmaceuticals

Approach: COUR’s nanoparticle therapies deliver disease-specific antigen or allergen to antigen-presenting cells (APCs) in the spleen and liver via natural, non-inflammatory, phagocytic pathways.

Strategic Area: Immunotherapies

T1D Funding Impact: Moving a T1D program into the clinic

Orizuru Therapeutics

Approach: Orizuru Therapeutics was founded out of research from Kyoto University and is developing iPSC derived islets and cardiomyocytes

Strategic Area: Beta Cell Therapies

T1D Funding Impact: Moving a T1D program into the clinic

Eledon Pharmaceuticals

Approach: Clinical stage transplantation company

Strategic Area: Immunotherapies

T1D Funding Impact: Supporting exploratory clinical studies in T1D transplantation

Imcyse

Approach: Developping a new class of specific immunotherapeutic vaccines.

Strategic Area: Immunotherapies

AltruBio

Approach: AltruBio is a clinical stage company with a tetravelent antibody targeting PSGL1 for T cell mediated autoimmune and autoinflammatory diseases.

Strategic Area: Immunotherapies

T1D Funding Impact: Supporting aPSGL-1 clinical development

Nipuna Therapeutics

Approach: Nipuna Therapeutics is a stealth-stage company focused on precision immunology

Strategic Area: Immunotherapies

T1D Funding Impact: Advancing precision immunology therapies

Jaguar Gene Therapy

Approach: Leveraging gene therapy for patients suffering from severe genetic diseases.

Strategic Area: Beta Cell Therapies

T1D Funding Impact: Enabling a gene therapy program aimed at beta cell regeneration.

ZagBio

Approach: Zag Bio is working to discover and develop therapies targeted directly to the thymus, with the goal of generating central immune tolerance.

Strategic Area: Immunotherapies

T1D Funding Impact: Developing thymus-targeted tolerogenic therapies

Viacyte

Approach: ViaCyte, Inc. operates as a regenerative medicine company that primarily focuses on developing a cell replacement therapy for the treatment of diabetes. Its development portfolio includes VC-01 product candidate, a cell replacement therapy for the treatment of type 1 diabetes.

Strategic Area: Beta Cell Therapies